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DOI 10.1186/s12915-015-0136-2RESEARCH ARTICLE Open AccessMolecular basis of sugar recognition by
collectin-K1 and the effects of mutations
associated with 3MC syndrome
Umakhanth Venkatraman Girija1,2, Christopher M Furze1, Alexandre R Gingras2,3, Takayuki Yoshizaki4,
Katsuki Ohtani4, Jamie E Marshall1, A Katrine Wallis5, Wilhelm J Schwaeble1, Mohammed El-Mezgueldi2,
Daniel A Mitchell6, Peter CE Moody2, Nobutaka Wakamiya4 and Russell Wallis1,2*Abstract
Background: Collectin-K1 (CL-K1, or CL-11) is a multifunctional Ca2+-dependent lectin with roles in innate immunity,
apoptosis and embryogenesis. It binds to carbohydrates on pathogens to activate the lectin pathway of complement
and together with its associated serine protease MASP-3 serves as a guidance cue for neural crest development. High
serum levels are associated with disseminated intravascular coagulation, where spontaneous clotting can lead
to multiple organ failure. Autosomal mutations in the CL-K1 or MASP-3 genes cause a developmental disorder
called 3MC (Carnevale, Mingarelli, Malpuech and Michels) syndrome, characterised by facial, genital, renal and limb
abnormalities. One of these mutations (Gly204Ser in the CL-K1 gene) is associated with undetectable levels of
protein in the serum of affected individuals.
Results: In this study, we show that CL-K1 primarily targets a subset of high-mannose oligosaccharides present on
both self- and non-self structures, and provide the structural basis for its ligand specificity. We also demonstrate
that three disease-associated mutations prevent secretion of CL-K1 from mammalian cells, accounting for the
protein deficiency observed in patients. Interestingly, none of the mutations prevent folding or oligomerization of
recombinant fragments containing the mutations in vitro. Instead, they prevent Ca2+ binding by the carbohydrate-
recognition domains of CL-K1. We propose that failure to bind Ca2+ during biosynthesis leads to structural defects
that prevent secretion of CL-K1, thus providing a molecular explanation of the genetic disorder.
Conclusions: We have established the sugar specificity of CL-K1 and demonstrated that it targets high-mannose
oligosaccharides on self- and non-self structures via an extended binding site which recognises the terminal
two mannose residues of the carbohydrate ligand. We have also shown that mutations associated with a rare
developmental disorder called 3MC syndrome prevent the secretion of CL-K1, probably as a result of structural
defects caused by disruption of Ca2+ binding during biosynthesis.
Keywords: Complement activation, structural biology, C-type lectin, 3MC syndromeBackground
Collectin-K1 (CL-K1) is a multifunctional secreted
pattern-recognition lectin with key roles in host defence,
tissue homeostasis and embryogenesis [1,2]. It binds to
pathogen-associated molecular patterns and activates
mannan-binding lectin (MBL)-associated serine proteases* Correspondence: rw73@le.ac.uk
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article, unless otherwise stated.(MASPs-1, −2 and −3) to initiate the lectin pathway of
complement activation, and stimulate immune and in-
flammatory processes [3,4]. It also binds to apoptotic cells
and may function as a scavenger receptor to facilitate
their clearance as has been shown for other collectins.
Elevated serum levels are associated with a severe clotting
disorder called disseminated intravascular coagulation,
characterised by systemic coagulation and microvascular
thrombi, that often leads to multiple organ failure [5].
During embryogenesis, CL-K1 is highly expressed ined Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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bodies and together with MASP-3 probably serves as a
guidance cue for neural crest cell migration by recognising
specific endogenous carbohydrate epitopes [6]. Separate
autosomal mutations in the genes encoding CL-K1 or
MASP-3 lead to a rare autosomal recessive disorder called
Carnevale, Mingarelli, Malpuech and Michels (3MC)
syndrome, associated with craniofacial dysmorphism,
mental retardation and genital, renal and limb abnor-
malities, highlighting the importance of these com-
plexes during development.
CL-K1 is a member of the collectin family of animal
lectins with an N-terminal collagen-like domain linked
to C-terminal carbohydrate-recognition domains (CRDs)
via a helical neck [7]. The collagenous stems are tethered
together at the N-terminus to form characteristic bouquet-
or fan-shaped structures. CL-K1 can form homooligomers
as well as heterooligomers with the related molecule
collectin-L1 (CL-L1) [8]. Clusters of CRDs recognise their
carbohydrate targets through multiple weak interactions
[9]. Ca2+ plays an essential role in this process by forming
a ternary complex with the protein and the glycan ligand
and by stabilising the CRDs [10-12]. CL-K1 binds to a var-
iety of intact bacteria, fungi, and viruses including Escheri-
chia coli, Candida albicans and Influenza A virus [3]. It
also binds to DNA, explaining at least in part how it targets
apoptotic cells [13]. Although selective for mannose and
fucose, CL-K1 binds only weakly to monosaccharides (IC50
approximately 20 mM) compared to MBL (KD approxi-
mately 1 mM) [14] and other collectins, and little is known
about its specificity towards oligosaccharides on self- or
non-self structures [3].
Three separate disease-associated mutations have been
identified in the coding region of the CL-K1 gene. All
lead to changes in the primary structure of the CRD:
two result in single amino acid substitutions: Ser169Pro
and Gly204Ser and the third leads to the deletion of
Ser217. CL-K1 is undetectable in the serum of individuals
homozygous for the Gly204Ser mutation, implying that it
is either not secreted or is degraded in serum. However,
the other disease-associated mutations have not been
characterised [6].
Here we show that CL-K1 primarily recognises a sub-
set of high-mannose oligosaccharides containing the di-
saccharide motif: Man(α1-2)Man found on both self and
non-self structures. It binds to both sugar moieties, in
contrast to other collectins that only recognise the ter-
minal sugar. We also show that all three mutations asso-
ciated with 3MC syndrome prevent normal secretion
from mammalian cells probably as a result of structural
changes caused by the failure to bind Ca2+ during biosyn-
thesis. The protein deficiency would prevent the normal
recognition processes of CL-K1/MASP-3 complexes dur-
ing development, leading to the 3MC phenotype.Results
Sugar specificity of CL-K1 towards self and non-self ligands
To characterise the sugar specificity of CL-K1, we ini-
tially screened a selection of glycoproteins with well-
characterised glycans (Figure 1A). Blot analysis revealed
binding to immunoglobulin M (IgM), thyroglobulin and
yeast invertase and mannan, but not to RNAse B, fetuin
or IgG. The most discernible difference in the pattern of
recognition was the presence of high-mannose oligosac-
charides on the glycoproteins that were recognised,
compared to predominantly complex sugars on those
that were not. An exception was RNAse B, which pos-
sesses a single N-linked glycosylation site, mainly occupied
by Man5 (approximately 60%) but with some Man6-Man9
[15]. To explore carbohydrate binding further, the binding
kinetics was determined for yeast invertase, mannan and
gp120 from HIV that all possess high-mannose oligosac-
charides. CL-K1 bound tightly to all three glycoproteins,
but not to milk lactoferrin that contains complex sugars
(Figure 1B). In each case, the data fitted best to a two-
complex model and the kinetic parameters are presented
in Table 1. To confirm that carbohydrate binding leads to
activation of complement, C3b deposition was measured
on mannan in whole human serum depleted of endogen-
ous lectins (Figure 1C). CL-K1 activated complement with
only 2.5-fold lower activity than human MBL.
To examine binding to individual glycans, fluorophore-
labelled CL-K1 was used to probe a broad screen of
mammalian carbohydrates using the Core H Glycan array
technology facility at The Consortium for Functional Gly-
comics [16]. The array consisted of 377 natural and syn-
thetic mammalian glycans attached to the surface of a
glass microscope slide via covalent amide linkages. The
relative fluorescence signal provides an accurate indication
of the order of affinities [17]. Consistent with the glyco-
protein data, the best ligands were all high-mannose oli-
gosaccharides (Figure 2A and Additional file 1), but not
all of these were recognised. Mammalian high-mannose
structures comprise a Man5 core attached to the protein
via two GlcNAc residues, with α1-2 linked sugars at the
non-reducing termini (Figure 2C). CL-K1 only recog-
nised those structures containing at least one terminal
Man(α1-2)Man epitope. For example, it bound tightly to
Man6, Man7, Man8 and Man9 but not to the Man5 core
(ligand 310) that comprises only α1-3 and α1-6 linkages.
It also bound to smaller glycans containing the essential
disaccharide epitope, for example, the trisaccharide,
Man(α1-2)Man(α1-3)Man (ligand 189). The GlcNAc resi-
dues were neither necessary nor enhanced binding (for
example, compare Man9GlcNac2, ligand 192, and Man9,
ligand 312). This pattern of recognition is different from
other collectins, such as MBL and pulmonary-surfactant
protein D that typically recognise the terminal sugar alone
(mannose, fucose or N-acetyglucosamine) [18,19]. It is
Figure 1 Glycoprotein binding and complement activation by CL-K1. A) Immunoblot of CL-K1 binding to immobilised mammalian and yeast
glycoproteins. B) Surface plasmon resonance of CL-K1 binding to glycoproteins. CL-K1 was immobilised on the chip surface (6,000 response
units) and six two-fold dilutions of each glycoprotein were injected at a starting concentration of 200 nM. C) Complement component C3b was
measured on mannan following incubation with human serum, depleted of endogenous lectins, and supplemented with either CL-K1 or human
recombinant MBL. C3b and its breakdown products were detected by absorbance using an anti-human C3c antibody with alkaline phosphatase-
conjugated goat anti-rabbit secondary antibody and p-nitrophenyl phosphate as the substrate. Protein concentrations were calculated based on
the molecular masses of CL-K1 and MBL trimers (78 kDa in each case). CL-K1, collectin-K1; MBL, mannan-binding lectin.
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or DC-SIGNR that target larger high-mannose oligosac-
charides preferentially (Man5 to Man9) [17]. To quantify
the differences in affinities, we compared binding to three
different epitopes that all form part of a high-mannose
oligosaccharide. Inhibition by Man(α1-2)Man (IC50 of
0.02 mM) was 10- and 8-fold greater than for the Man3
and Man5 core structures, and >300-fold greater than
for mannose alone (Figure 2C). Thus, CL-K1 primarily
recognises the terminal disaccharide of the glycan, ra-
ther than the terminal sugar alone, explaining its un-
usual binding properties.Table 1 Kinetics of binding of CL-K1 to glycoproteins
Glycoprotein kon koff KD
(M−1 s−1) (s−1) (nM)
Mannan 1.6 ± 0.3 × 103 <1.0 × 10−6 <0.8
1.0 ± 0.2 × 106 3.0 ± 0.2 × 10−4 0.31 ± 0.9
Invertase 6.8 ± 0.4 × 104 1.2 ± 0.2 × 10−3 18 ± 4
6.7 ± 0.5 × 105 <1.0 × 10−6 <0.002
gp120 1.5 ± 0.3 × 105 1.1 ± 0.2 × 10−3 8 ± 4
>1 × 106 <1.0 × 10−6 <0.001
All data were fitted to a two-complex binding model. Values of kon above 1 ×
106 M−1 s−1 and koff below 1.0 × 10
−6 s−1 exceed the reliable detection limits of
the instrument, so are given as lower and upper limits respectively. Data are
mean ± error from two experiments.CL-K1 also bound to subsets of fucosylated glycans, in-
cluding those containing Lewisa, Lewisy and blood group B
antigens as well as to a selection of structures containing
blood group H antigens (Figure 2A). Most fucosylated
sugars were not recognised, however, suggesting that CL-K1
contacts multiple monosaccharide moieties in each glycan
and that the chemical environment of the binding epitope is
important. Binding to almost all ligands was Ca2+-dependent
(see Additional file 1), compatible with the pivotal role of
Ca2+ in carbohydrate recognition by C-type lectins. An ex-
ception was 9-O-acetylneuraminic acid, which gave a similar
binding signal in the presence and absence of Ca2+, implying
that it interacts with a distinct and independent binding site
on CL-K1.
Structure of CL-K1 in complex with a disaccharide ligand
In order to determine the precise specificity and mech-
anism of carbohydrate recognition by CL-K1, a recom-
binant trimeric fragment comprising the neck and CRDs
was produced in E. coli, refolded from inclusion bodies
and was crystallized in the presence of Ca2+, and struc-
tures were determined both with and without its pri-
mary ligand, Man(α1-2)Man (PDB: 4YLI and 4YMD for
the CL-K1 trimer and the trimer bound to Man(α1-
2)Man; Table 2). The structures confirm that the CL-K1
fragment is a homotrimer with the three CRDs linked
Figure 2 Carbohydrate binding by CL-K1. A) Glycan-array analysis of CL-K1. Key: open circle, mannose; closed circle, galactose, closed square,
N-acetylglucosamine; closed diamond, N-acetylneuraminic acid; open square, N-acetylgalactosamine; open diamond, glucose; and triangle, fucose.
High-mannose and blood group/Lewis antigen ligands are in green and blue. B) Inhibition of CL-K1 binding to immobilized yeast invertase (10
μg per well) by high-mannose epitopes (Man2: α1-2 mannobiose; Man3: α1-3, α1-6 mannotriose; Man5: α1-3, α1-3, α1-6 Mannopentaose). Values
are the mean ± error from duplicate measurements. C) Schematic representation of the mammalian high-mannose glycan (Man9GlcNAc2). Boxes
show the two Man3 core structures that together form the Man5 core. CL-K1, collectin-K1.
Venkatraman Girija et al. BMC Biology  (2015) 13:27 Page 4 of 13via an α-helical coiled coil (Figure 3). The asymmetric
unit of each crystal contained two trimers with each
CRD bound to three Ca2+. Density for the sugar was
present for four of the six polypeptides (Figure 3A and
B). In the ligand complex, the reducing mannose of the disac-
charide binds to the Ca2+ common to all C-type lectins, with
the equatorial 3- and 4-OHs of the sugar forming coordin-
ation bonds with the Ca2+ and hydrogen bonds to surround-
ing Asn, Asp and Glu residues that also serve as Ca2+ ligands.
The interaction is unusual, however, because it involves the
penultimate sugar (internal in a high-mannose oligosacchar-
ide) rather than the terminal sugar (non-reducing) that is
recognised by other collectins (Figure 3C and D) [10,19]. In
addition, the terminal mannose forms hydrogen bonds to the
carboxylate group of Glu244 and the guanidinium group ofArg200 to form a small hydrogen-bonding network that stabi-
lises the interaction compared to mannose alone, providing
an explanation for its binding specificity. Comparison of the
bound and unbound structures reveals no major conform-
ational changes upon carbohydrate recognition. The inter-
action is somewhat reminiscent of glycan binding by DC-
SIGN and DC-SIGNR, which also target high-mannose oligo-
saccharides via internal sugar moieties (Figure 3E). The ligand
specificities of CL-K1 and DC-SIGN/DC-SIGNR are signifi-
cantly different, however, as noted above.
Ca2+ stabilises CL-K1 by organising the binding loops of
the CRDs
Ca2+ is integral to the structure and function of CL-K1
(Figure 3). It not only interacts directly with the
Table 2 Data collection and refinement statistics
Structural data CL-K1 trimer CL-K1 +Man2
PDB code 4YLI 4YMD
Data collection
Beamline Diamond I04 Diamond I04-1
Space group P 1 21 1 P 1 21 1
a, b, c, Å 73.0 107.6 77.8 71.9 106.7 78.4
α, β, γ, ° 90, 91.5, 90 90, 92.2, 90
Resolution, Å 48.21-2.45 (2.538-2.45) 44.08-2.87 (2.973-2.87)
Rsym 0.054 (0.48) 0.052 (0.54)
I/σI 10.1 (2.0) 11.2 (1.8)
Completeness, % 95.5 (87.2) 91.0 (93.6)
Redundancy 3.3 (3.1) 2.9 (2.9)
Refinement
Resolution, Å 48.21-2.45 (2.538-2.45) 44.08-2.87 (2.973-2.87)
Unique reflections 42224 (3791) 24670 (2518)
Rwork/Rfree 0.1869/0.2212 0.2129/0.2607
No of atoms 7332 7220
Protein 7162 7062
Ligands/ion 121 152
water 49 6
B-factors, Å2 74.5 93.2
macromolecules 74.5 93.0
ligands 76.4 105.6
water 60.7 62.6
rms deviations
Bond lengths, Å 0.003 0.003
Bond angles, ° 0.62 0.77
The highest-resolution shell is shown in parentheses.
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the CRD. We used the intrinsic fluorescence of the tri-
meric fragment as a probe to measure Ca2+ binding.
Each CRD contains two tryptophan residues, which to-
gether form part of the hydrophobic core and are sensi-
tive to changes in the conformation of the adjacent Ca2
+-binding loops. Addition of Ca2+ caused a large enhance-
ment of the native fluorescence (approximately 50%) com-
bined with a shift in λem, max to a shorter wavelength
(from 346 nm to 339 nm), as the tryptophans move to a
more hydrophobic environment (Figure 4A). The KD was
measured as 0.43 mM by titration with Ca2+, with a Hill
coefficient of 2.4 (Figure 4B). Thus, although only one Ca2
+ interacts with the ligand directly, binding itself is highly
cooperative, with all three Ca2+ being important.
We also investigated the role of Ca2+ towards the stability
of the CRDs of CL-K1 using urea denaturation. Unfolding
of the CRD/neck fragment was accompanied by a dramatic
quenching of the fluorescence and a shift in λem, max to ap-
proximately 354 nm as the tryptophans become exposedto the polar solvent (Figure 4A). Unfolding could be ex-
plained by a simple two-state transition, both in the pres-
ence and absence of Ca2+. However, the midpoint
(denaturation concentration) was 2.4 M and 1.4 M urea for
the Ca2+-bound and -free forms (Figure 4C), indicating
that Ca2+ stabilises the CRDs.
The three Ca2+ interact with residues primarily from loops
towards the top of the CRD (Figure 5A). In the absence of
Ca2+, these regions are likely to be more flexible. To investi-
gate this possibility, we compared the susceptibility of the
trimeric CL-K1 fragment towards trypsin, which preferen-
tially cleaves disordered regions of proteins. The Ca2+-free
form was highly sensitive to trypsin (Figure 4E). By con-
trast, an approximately 15 kDa fragment was generated in
the presence of Ca2+ that was relatively resistant to further
proteolysis (Figure 4E and F). This fragment was identified
as the CRD by Edman degradation, beginning at residue
Glu148. By measuring proteolysis in the presence of in-
creasing concentrations of Ca2+, the apparent KD for cal-
cium was determined as approximately 1 mM, in good
agreement with fluorescence data (Figure 4D and F).
Thus, Ca2+ stabilises the CRD by tethering the binding
loops together. In the absence of Ca2+, these loops become
disordered and more exposed.
Mutations associated with 3MC syndrome prevent
secretion of CL-K1
As well as explaining the mode of carbohydrate recognition,
the structures of CL-K1 also reveal the location of residues
that are altered in the 3MC syndrome (Ser169, Gly204 and
Ser217). Gly204 and Ser217 are located at the base of loop L1
(Figure 5A) that forms part of the binding site for two of the
three Ca2+. The carbonyl group of Gly204 forms a hydrogen
bond with the amide of Ser217, helping to anchor the loop to
the side of the domain. Ser169 forms part of one of two helices
at the base of the CRD, close to the helical neck of the trimer.
To characterise the disease-associated mutations, corre-
sponding changes were introduced into the cDNA of CL-
K1, and proteins were expressed in Chinese hamster ovary
cells. Immunoblotting of media from transfected cells re-
vealed that although wild-type CL-K1 was secreted as ex-
pected, no protein was detected in the media of cells
transfected with any of the mutant cDNAs (Figure 5B),
implying that the encoded proteins are not secreted. This
conclusion would explain the protein deficiency in indi-
viduals with the Gly204Ser mutation and suggests that
those individuals with Ser169Pro or ΔSer217 mutations are
also likely to be deficient in CL-K1.
Defective Ca2+ binding by CL-K1 containing
disease-associated mutations probably leads to
elimination during biosynthesis
Surprisingly, when recombinant fragments of CL-K1
(neck and CRDs) containing the mutations (subsequently
Figure 3 Structure of a trimeric fragment of CL-K1 bound to a mannose disaccharide. A and B) top and side views. The carbohydrate is in white
and Ca2+ in pink. Comparison of carbohydrate binding by C) CL-K1; D) mannan-binding lectin (PDB: 1KWY) and E) DC-SIGN (PDB: 2IT5). Polar
interactions are shown by dotted lines. The penultimate sugar moiety (internal in a high-mannose oligosaccharide) is in grey. CL-K1, collectin-K1.
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they refolded like the wild-type fragment, and good yields
of purified protein were isolated (1 to 2 mg/L of culture).
This finding was unexpected because we anticipated that
the mutations would severely destabilise the CRDs, thus
preventing folding. It was therefore of interest to charac-
terise these fragments in more detail to attempt to under-
stand why the mutations are deleterious and prevent
secretion in vivo.
Collectins normally fold in the endoplasmic reticulum
(ER), in the presence of Ca2+ where resident chaperones
monitor the folding status of proteins [20]. Misfolded or
partially folded proteins with exposed hydrophobic re-
gions are recognised by these chaperones, and are targeted
for elimination via the ER-associated protein degradation
pathway [21]. Consequently, any structural defects caused
by the mutations are likely to prevent secretion. Circular
dichroism indicated that all three variants were folded,
with spectra characteristic of the α/β structure of the
neck + CRD regions (Figure 6B). This finding was con-
firmed by fluorescence spectroscopy and urea denatur-
ation experiments (Figure 7A and B; described in moredetail below). The first clue that they were defective was
from gel filtration analysis. Like many lectins, CL-K1
binds to dextran, so is retarded on gel filtration columns
such as Superdex. This binding could be prevented by
excess mannose as a competitive inhibitor, or by ethylene-
diaminetetraacetic acid (EDTA) that chelates the Ca2+
(Figure 6A), whereupon the wild-type fragment eluted at
the position of a homotrimer (47 kDa). The variant frag-
ments were also trimers, but did not bind to the dextran
matrix even in the presence of Ca2+, implying loss of
carbohydrate binding. To confirm this possibility, we mea-
sured binding to yeast invertase. Both full-length CL-K1
and the wild-type fragment bound to the invertase, but
the three variant fragments did not bind (Figure 6C).
Thus, although folded and assembled into trimers, the
mutations disrupt the CRDs preventing normal interac-
tions with carbohydrate ligands.
The most likely reason for the failure to bind carbohy-
drate is loss of Ca2+ binding. As described above, failure
to bind Ca2+ destabilises the CRDs and exposes flexible
loop regions. The presence of such defects during bio-
synthesis would likely lead to elimination of CL-K1
Figure 4 Ca2+ stabilises the CRDs of CL-K1. A) Fluorescence spectra of the CL-K1 fragment in different buffers. The λex was 280 nm. B) Ca2+
binding to the CL-K1 fragment measured by fluorescence. Measurements were recorded at an λem of 345 nm. C) Urea denaturation in the
presence and absence of Ca2+ (2 mM). D) Proteolysis of CL-K1 in the presence of increasing concentrations of Ca2+ (two fold dilutions starting
at 5 mM). Samples were separated by SDS-PAGE and gels were scanned to determine the amount of CL-K1 remaining. The amount of trypsin
was 0.5% (w/w). The intensities of bands corresponding to the neck and CRD and the CRD alone were combined. A sample gel is shown in F).
E) Proteolysis of CL-K1 in the presence and absence of Ca2+. Two fold serial dilutions of trypsin were used at a starting concentration of 2%
(w/w). In all experiments data are mean ± error from two separate experiments. CL-K1, collectin-K1; CRD, carbohydrate-recognition domain.
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tested Ca2+ binding using fluorescence assays described
above. Addition of Ca2+ to the variant CL-K1s did not
cause the changes in quantum yield or λem, max that were
observed upon Ca2+ binding by the wild-type fragment
(Figure 7A). Furthermore, urea denaturation curves re-
sembled the Ca2+-free form, even in the presence of Ca2+,
with denaturation concentrations of 1.5, 1.3 and 1.4 M
for Ser169Pro, Gly204Ser, ΔSer217 proteins respectively
(Figure 7B). Likewise, each of the variants was equally
sensitive to trypsin in the presence or absence of Ca2+
(Figure 7B). Thus, all three mutations induce a common
structural defect that arises due to the failure to bind to
Ca2+. In vivo, such defects are likely to be detected by
chaperones in the ER during biosynthesis leading to
elimination. In this way, the mutations would preventnormal secretion of CL-K1, accounting for the protein
deficiency in patients with 3MC syndrome.
Discussion
The data described here explain for the first time how
CL-K1 is able to target self- and non-self carbohydrate
ligands to fulfil its diverse biological functions. Man(α1-
2)Man epitopes are found at the non-reducing termini
of many, but not all, mammalian high-mannose sugars.
They are also found on fungal, viral and bacterial struc-
tures. For example, mannan from cell walls of C. albi-
cans, a known target of CL-K1 [3], is rich in α1-2 linked
mannose oligosaccharides [22]. Likewise, high-mannose
oligosaccharides on viral haemagglutinin and gp120
enable CL-K1 to bind to Influenza A virus and HIV [3].
High-mannose oligosaccharides themselves represent only
Figure 5 No secretion of variant CL-K1s containing mutations
associated with 3MC syndrome. A) Structure of the CRD of CL-K1
showing the position of mutations associated with 3MC syndrome.
Secondary structure features are labelled based on the structure of
MBL [38]. Polar interactions are indicated by dotted lines. B) Secretion
of wild type and variant CL-K1s from mammalian cells. Serum-free
medium from Chinese hamster ovary cells (20 μL) transfected with
wild-type (WT) or variant cDNAs was separated on a 15% SDS-PAGE
gel under non-reducing conditions and blotted onto a nitrocellulose
membrane. Secreted CL-K1 was detected using rabbit polyclonal
anti-CL-K1 antibodies. Purified wild-type CL-K1 (approximately 20
ng) was used as a positive control. CL-K1, collectin-K1; CRD,
carbohydrate-recognition domain; MBL, mannan-bindng lectin;
3MC, Carnevale, Mingarelli, Malpuech and Michels.
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and glycolipids display complex oligosaccharides that are
based on a Man3GlcNac2 core not targeted by CL-K1, in
which the two antennae are decorated with other sugars.
The difference in specificity of CL-K1 compared to other
collectins is due to the presence of an extended binding
site on the CRD (Figure 3C). Whilst unusual for a col-
lectin, additional interactions have been described for
other C-type lectins including DC-SIGN, selectins and
the macrophage receptor Mincle, each with different
ligand preferences [23].Heterocomplexes of CL-K1 and CL-L1 polypeptides
may recognise additional ligands that are not targeted by
CL-K1 homooligomers as a result of contacts mediated
through the CRD of CL-L1. Like CL-K1, CL-L1 has a
preference for ligands possessing mannose and/or fucose
epitopes, although little is known about its specificity to-
wards oligosaccharides on self or non-self structures.
The presence of CL-K1/CL-L1 complexes as well as CL-
K1 homooligomers in serum and in other tissue fluids
may serve to increase the range of pathogens targeted by
the lectin pathway. It is currently unclear, however, if
CL-L1 participates in developmental processes or is in-
volved in the aetiology of 3MC syndrome.
Ca2+ is essential for the structure and function of C-
type lectins, because it stabilises the CRDs and helps
position the loops in the correct arrangement for ligand
binding. Although we were unable to crystallise CL-K1
in the absence of Ca2+, the structure of a Ca2+-free form
of MBL reveals that the core of the CRD is largely un-
changed but the loops are positioned differently with
some regions being undetectable in the electron density,
implying considerable flexibility [11]. A similar scenario
for the CL-K1 variants would explain why the CD spec-
tra are similar to wild type but the CRDs are much more
sensitive to proteolysis.
Gly204 and Ser217 are located at the base of Ca2+-bind-
ing loop L1 (Figure 5A), so the disease-associated muta-
tions probably interfere with the packing of this loop
against the CRD, thereby preventing Ca2+ binding. The ef-
fects of the Ser169Pro mutation within Helix 1 are less
clear. Nevertheless, the introduction of a proline residue
in place of the serine is likely to destabilise the helix and
preclude the normal interactions with the CRD. Notably,
Tyr163 at the top of the helix forms part of the hydro-
phobic core and packs against residues in loop 1, form-
ing a hydrogen bond with Asn206. Disruption of these
contacts probably prevents Ca2+ binding, leading to the
disease phenotype.
Folding of CL-K1, like other collectins, probably pro-
ceeds in a C- to N-terminal in which folding of the neck
and CRDs nucleates assembly of the N-terminal collagen-
like domains [20]. All three variant fragments folded and
trimerised in vitro, so folding is still thermodynamically
favourable, despite the mutations. It is thus likely that at
least some polypeptides fold in vivo. Nevertheless, the
CRDs will be defective with exposed, disordered regions,
so variants are likely to be retained and subsequently elim-
inated by the ER-associated protein degradation pathway
[21]. The possibility that the mutations prevent folding
in vivo (but not in vitro) cannot be completely ruled out.
However, this scenario would seem less likely, in particular
because none of the mutations are greatly destabilising
per se (Figure 7B). Instead, the decrease in stability in each
case can be accounted for by the failure to bind to Ca2+.
Figure 6 Characterisation of CL-K1 fragments containing disease-associated mutations. A) Gel filtration on a Superdex 200 (10/30 column) in 50
mM Tris–HCl at pH 7.4, containing 150 mM NaCl. The elution positions of conalbumin (75 kDa), ovalbumin (44 kDa) and ribonuclease A (13.7 kDa)
are indicated. Top, The wild-type CL-K1 fragment interacts with the column matrix in buffer containing Ca2+ (2 mM) but not in the absence of
Ca2+ (2 mM EDTA) or in the presence of inhibitory concentrations of mannose (200 mM). Bottom, None of the three CL-K1 variants interacts with
the column, even in the presence of Ca2+. B) CD spectra of the wild-type CL-K1 fragment and the disease-associated CL-K1 variants. C) Binding of
biotinylated invertase to full length CL-K1 and trimeric fragments. Values are the mean ± error from duplicate measurements. Tighter binding of
the full-length protein is due to its increased avidity. CL-K1, collectin-K1; EDTA, ethylenediaminetetraacetic acid.
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certain blood group antigens, including groups B and H,
is both interesting and unexpected. Lewis y is expressed
mainly during embryogenesis, and in adults expression
is restricted to granulocytes and epithelial surfaces [24].
Elevated levels are also found in most epithelial-derived
human carcinomas, including breast, ovary, prostate,
colon cancers, and high levels are correlated with poor
prognosis [24]. Platelets and coagulatory factors such as
Von Willebrand Factor are all decorated with blood group
antigens, and crosslinking of these components possibly
leading to complement activation might account for the
link between elevated CL-K1 serum levels and dissemi-
nated intravascular coagulation [25]. Notably, activation of
the lectin pathway itself promotes activation of the clot-
ting cascade potentially compounding the problem [26].
The larger binding pocket on CL-K1 and the resulting en-
hanced affinity for its glycan ligands compared to othercollectins suggest that it may be possible to design inhibi-
tors that selectively block ligand binding. These would
have therapeutic potential for the treatment of dissemi-
nated intravascular coagulation and other disorders
associated with profound activation of the innate im-
mune and/or coagulation systems, such as in ischaemia-
reperfusion injury.
Conclusions
In conclusion, we have shown that CL-K1 binds to high-
mannose oligosaccharides and fucosylated sugars includ-
ing blood group antigens and Lewis antigens. It binds to
high-mannose oligosaccharides via an extended binding
site that recognises the terminal two mannose residues.
In addition, we have shown that three naturally occur-
ring mutations associated with a severe developmental
disorder syndrome prevent secretion of CL-K1 from
mammalian cells, probably as a result of a failure to
Figure 7 Destabilisation of variant CL-K1s caused by the failure to bind to Ca2+. A) Fluorescence spectra of variant CL-K1 trimers in the presence
(solid line, 2 mM Ca2+) and absence of Ca2+ (dotted line, 2 mM EDTA) and in 6 M urea (dashed line). The λem, max of Ca2+ bound and Ca2+ free
forms of the wild-type fragment are indicated by vertical dotted lines. B) Unfolding of the variant CL-K1 (lower) fragments in urea. All experiments
were performed in the presence of 2 mM Ca2+ and data were recorded at 345 nM. Values are mean ± error from duplicate experiments. The
denaturation concentrations of Ca2+-bound and Ca2+-free forms of the wild-type fragment are indicated by vertical dotted lines. C) SDS-PAGE
gels (17.5%) showing proteolysis of variant CL-K1 fragments with two-fold serial dilutions of trypsin (highest concentration is 4% w/w). CL-K1,
collectin-K1; EDTA, ethylenediaminetetraacetic acid.
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ficiency would prevent normal developmental processes
mediated via CL-K1/MASP-3 complexes leading to
3MC syndrome.
Methods
Proteins
Bovine fetuin and RNAse B, human milk lactoferrin, yeast
invertase and yeast mannan were from Sigma-Aldrich
Company Ltd. (Gillingham, UK). Bovine thyroglobulin was
from GE Healthcare (Little Chalfont, UK). Human IgM
and IgG were from Athens Research & Technology, Inc.
(Athens, Georgia, USA). Recombinant HIV gp120 was pro-
duced in HEK293 cells [27]. Recombinant human MBL
was produced in CHO cells as described for rat MBL [28].
Production of full-length CL-K1 and trimeric fragments
For full-length protein, the cDNA was cloned into the
polylinker region of expression vector pED [29] andprotein was produced in Chinese hamster ovary cells
and purified by affinity chromatography on mannose-
Sepharose columns as described previously for MBL
[28,30]. A fragment of the cDNA encoding the neck and
CRD (beginning at residue Ser116) was cloned into the
polylinker of pET28a. Cells were grown in Power Prime
broth (Molecular Dimensions Limited (Newmarket, UK)),
induced during mid-log phase with IPTG (1 mM), and
harvested after growth at 37°C for an additional 16 hours.
Inclusion bodies were isolated and resuspended in 50 mM
Tris–HCl, containing 8 M urea and 5 mM dithiotreitol
(DTT) and protein was refolded by drop dilution into 50
mM Tris–HCl pH 8.0, containing 9.6 mM NaCl, 0.4 mM
KCl, 2 mM MgCl2, 2 mM CaCl2, 0.5 M arginine, 0.05%
polyethylene glycol 3,550, 1 mM GSH and 0.1 mM GSSH
at a final protein concentration of 0.1 mg/ml. Proteins
were purified by ion exchange chromatography on a 10
mL Q-Sepharose column, using a 0.05 to 1 M gradient of
NaCl in 20 mM Tris–HCl at pH 8.0, followed by gel
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in 20 mM Tris at pH 7.5 containing 50 mM NaCl and 2
mM CaCl2.
Binding of CL-K1 to glycoproteins
Two-fold serial dilutions of glycoprotein (0.5 μl at a start-
ing concentration of 2 mg/ml) were spotted on to a nitro-
cellulose membrane and allowed to dry for 30 minutes at
room temperature. The membrane was blocked with 5%
milk powder in 25 mM Tris–HCl, pH 7.4 containing 150
mM NaCl for two hours, washed with buffer + 0.5%
Tween-20 and then incubated with biotinylated CL-K1
(0.06 mg/ml) at room temperature for one hour. After
washing, the membrane was incubated with Streptavidin-
ALP conjugate (2ug/ml; Life Technologies Ltd (Paisley,
UK)) and developed with BCIP-NBT substrate (Sigma).
Glycan-array screen
Human CL-K1 directly labelled with Alexα-488 was di-
luted to 200 μg/ml in 20 mM Tris–HCl, pH 7.4 containing
150 mM NaCl, 2 mM MgCl2, 12 mM CaCl2, 1% BSA and
0.05% Tween 20. Labelled protein (70 μL) was applied to
the printed surface of the microarray chip coated with nat-
ural and synthetic glycans via amino linkers. The chip was
covered and incubated at room temperature in a humidi-
fied chamber for one hour. Binding was detected by meas-
uring the fluorescence associated with each glycan. Data
are the average of six replicates.
Surface plasmon resonance
CL-K1 was immobilised on the surface of a GLM sensor
chip (Bio-Rad Laboratories Ltd (Hemel Hempstead,
UK)) by amine coupling. Binding was measured in 10
mM Tris–HCl, pH 7.4 containing 140 mM NaCl, 2 mM
CaCl2 and 0.005% Tween 20 at a flow rate of 25 μl/mi-
nute and at 25°C. The protein surface was regenerated
in buffer containing 1 M NaCl and 5 mM EDTA.
Complement activation
Complement activation was measured by deposition of
complement component C3b on immobilised mannan.
Microtiter plates (Nunc) were coated with 2 μg mannan
overnight and incubated with 1/100 dilution of whole
human serum, previously depleted of endogenous lectins
by passage through two mannose-Sepharose columns
(2 × 0.5 ml matrix/mL of serum) in 4 mM barbital, 145
mM NaCl, 2 mM CaCl2, 1 mM MgCl2, pH 7.4, supple-
mented with recombinant human MBL or human CL-
K1. After incubation at 37°C for one hour and washes
with buffer containing 0.5% Tween-20, C3b was detected
using rabbit anti-human C3c antibody (Dako UK Ltd
(Ely, UK)) with alkaline phosphatase-conjugated goat
anti-rabbit secondary antibody (Sigma) and p-
nitrophenyl phosphate as the substrate.Circular dichroism
All measurements were recorded on a Jasco J-715 spec-
tropolarimeter in 10 mM phosphate buffer, pH 7.4 and
at 25°C using 6 μM protein.
Fluorescence spectroscopy
All experiments were carried out using a Fluoromax-4
(Horiba Jobin Yvon, Horiba UK Ltd (Middlesex, UK)) in-
strument with excitation wavelength at 280 nm, slit
widths of 2 nm and emission wavelength range of 300 to
400 nm. The λex was 280 nm. Protein samples (0.5 μM)
in 10 mM Tris–HCl, pH 7.4 containing 140 mM NaCl
were measured in the presence of 2 mM CaCl2, 1 mM
EDTA and 6 M urea. For urea denaturation, proteins (0.5
μM) were equilibrated in urea (0 to 6 M) for 15 minutes
at room temperature and measurements were recorded at
λem of 345 nm.
Proteolysis
CL-K1 (0.5 mg/ml) was incubated with trypsin (max-
imum concentration of 4% w/w) in 50 mM Tris–HCl
pH 7.5, containing 140 mM NaCl for one hour at 37°C.
Binding assays
MaxiSorb microtiter plates (Nunc) were coated with yeast
invertase by overnight incubation in 0.2 M carbonate-
bicarbonate buffer at pH 9.6 and at 4°C. Wells were
blocked with 5% BSA in 10 mM Tris-Cl, 140 mM NaCl,
pH 7.4 and incubated with biotinylated CL-K1 (50 nM)
mixed with dilutions of carbohydrate ligand for one hour
at room temperature. After washing, wells were incubated
with 1:2000 dilution of goat peroxidase conjugated anti-
biotin antibody (Sigma) and developed with tetramethyl-
benzidine (Sigma). Absorbance was measured at 450 nM.
CL-K1 binding to invertase was carried out in the same
way except that plates were coated with CL-K1 and incu-
bated with dilutions of biotinylated invertase.
Crystallization and structure determination
All crystals were grown using the sitting-drop vapour
diffusion method by mixing equal volumes (1.2 + 1.2 μL)
of protein and reservoir solution. Protein at approxi-
mately 3 mg/ml was mixed with 10% (vol/vol) ethanol
in 100 mM HEPES pH 7.0 containing 4 mM CaCl2.
Similar conditions were used to crystallize the complex,
except that Man(α1-2)Man (1 mM) was included in the
mixture. All crystals were transferred to reservoir solu-
tion containing 20% (vol/vol) glycerol, before storage in
liquid nitrogen and were maintained at 100 K during
data collection. Ligand (1 mM) was included in the
cryoprotection buffer for the complex. Diffraction data
were collected at beamlines I04 and I04-1 at Diamond
Light Source and were processed with iMosflm [31].
Phases were determined by molecular replacement with
Venkatraman Girija et al. BMC Biology  (2015) 13:27 Page 12 of 13Phaser [32] using the structure of pulmonary-surfactant
protein D [33] as a search model (PDB: 1B08). Models
were optimized by using cycles of manual refinement
with Coot [34] and refinement in Refmac5 [35], part of
the CCP4 software suite [36], and in Phenix [37].
Additional file
Additional file 1: Glycan-array analysis of CL-K1 in the presence
and absence of Ca2+.
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